Status:
RECRUITING
Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborating Sponsors:
Royal Brompton & Harefield NHS Foundation Trust
Royal Marsden Partners West London Cancer Alliance
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whet...
Detailed Description
1.1 Lung cancer \& Indeterminate Lung Nodule Surveillance Over 46,000 cases of lung cancer are diagnosed every year in the UK, making it the 3rd most common cancer type. Lung cancer is the biggest cau...
Eligibility Criteria
Inclusion
- Patients under active investigation or surveillance for incidental lung nodules
- Age \> 18.
Exclusion
- Active or previous diagnosis of malignancy (within 5 years preceding baseline scan).
- Inability to give informed consent.
- Active infection (including tuberculosis or fungal infection).
- Clinician-suspected or confirmed active or recent COVID-19 infection (less than 4 weeks before CT scan or required blood sampling date).
Key Trial Info
Start Date :
April 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2031
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05432739
Start Date
April 7 2021
End Date
January 1 2031
Last Update
June 15 2023
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Barking Havering and Redbridge University Hospitals NHS Trust
Goodmayes, Essex, United Kingdom, IG3 8YB
2
Calderdale and Huddersfield NHS Foundation Trust
Huddersfield, United Kingdom, HD3 3EA
3
Princess Alexandra Hospital
London, United Kingdom, CM20 1QX
4
Whittington Health NHS Trust
London, United Kingdom, N19 5NF